Back to Search
Start Over
Lilly s Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio in Patients with ER+, HER2- Advanced Breast Cancer
- Source :
- ENP Newswire. December 12, 2024
- Publication Year :
- 2024
-
Abstract
- ENPNewswire-December 12, 2024--Lilly s Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio in Patients with ER+, HER2- Advanced Breast Cancer (C)2024 ENPublishing - [...]
- Subjects :
- Eli Lilly and Co.
Verzenio (Medication)
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- ENP Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.819657653